A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT GmbH participated in the round. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the Company through its prestigious GO-Bio program.
Captain T Cell develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies. Using a toolbox of next-generation technologies, Captain T Cell generates TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In preclinical in vivo models, the Company has been able to completely eradicate aggressive tumors using these efficacy-enhanced T cells. A key technology established by the Captain T Cell team is its proprietary TCR-ALLO platform for off-the-shelf treatment of solid tumors. The TCR-ALLO platform is a versatile tool that can be expanded to a variety of cancer indications.
Dr. Felix Lorenz, CEO of Captain T Cell, said: “This successful financing round allows us to accelerate our high-potential therapies and brings us closer to providing life-saving options for patients underserved by current treatments. We are steadfast in our mission to progress our lead candidate towards the clinic and to establish our TCR-ALLO platform as a leader in off-the-shelf solid tumor therapeutics.”
Further information can be found here: https://www.captaintcell.com/news/captain-t-cell-secures-seed-financing
